+352 464 010 600
No fees for performance
No up front fees
No debt or derivatives
No market timing
No index hugging
Understand more of what we are trying to achieve
Download the Owners Manual
Fundsmith Annual Shareholders' Meeting 2018
23 March 2018
Fundsmith Annual Shareholders' Meeting 2017
24 April 2017
ASM 2016 - Should you buy bonds?
22 March 2016
View all Fundsmith TV
What we are saying
Fundsmith Appoints Three New Partners
August 02 2018
Fundsmith LLP, the fund management company founded by Terry Smith, announces the appointment of Conrad Rey, Greville Ward and Daniel Washburn as Partners, subject to FCA approval.
Fundsmith Sustainable Equity Fund Wins Best New Fund At Money Marketing Awards
July 04 2018
The Fundsmith Sustainable Equity Fund ('FSEF'), which launched in November 2017, has won the ‘Best New Fund’ category at the Money Marketing Awards 2018. Money Marketing chose FSEF as the winner for its “credibility in the market and high competitive potential”.
What others are saying
This is Money - Why investors can't get enough of Fundsmith: How City veteran Terry Smith took Buffett-style investing to the top of the fund charts
January 22 2018
Fundsmith has developed a considerable fan club of investors and it is not difficult to see why. The Fundsmith Equity fund topped the bestseller lists of both the Bestinvest and AJ Bell DIY investment platforms last year and has returned a whopping 266 per cent in a little over seven years since it was launched.
The Guardian – Terry Smith – the man who beat the market in 2017
December 30 2017
Terry Smith has emerged as Britain’s top investment performer once again after another year of stellar returns.
What Terry Smith is saying
Financial Times – ESG? SRI? Is your green portfolio really green?
January 18 2018
In his article for FTfm, Terry Smith discusses sustainable investing and questions how green your portfolio really is.
Financial Times – AstraZeneca is beginning to look like Tesco
August 04 2017
In his latest article for FT Money, Terry Smith believes that AstraZeneca’s problems go much deeper than its recent setback for a single drug.
See all news